GENE EXPRESSION BIOMARKERS OF LAQUINIMOD RESPONSIVENESS
摘要
This invention provides a method of predicting clinical responsiveness to laquinimod therapy in a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising evaluating expression of a biomarker in the subject. This invention also provides a method of treating said subject comprising determining whether the subject is a laquimmod-responder by evaluating expression of a biomarker. Also provided is laquinimod or a pharmaceutical composition comprising laquinimod for use in treating said subject, and a therapeutic package for use in dispensing to said subject, wherein the subject has been identified as a laquimmod-responder or expression of a biomarker in the subject is up-regulated or suppressed.
申请公布号
WO2015038963(A1)
申请公布日期
2015.03.19
申请号
WO2014US55502
申请日期
2014.09.12
申请人
TEVA PHARMACEUTICAL INDUSTRIES, LTD.;TEVA PHARMACEUTICALS USA, INC.;TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.;HAYARDENY, LIAT;ACHIRON, ANAT;GUREVICH, MICHAEL